ImmuPharma (LON:IMM) Shares Up 9.5% - Here's What Happened

Key Points

• ImmuPharma's stock price increased by 9.5%, reaching a high of GBX 14.20 after closing at GBX 11.05, with trading volume up 176% compared to its average.
• The company reported a quarterly loss per share of GBX (0.38) and analysts project a negative earnings per share of -339.00 for the current fiscal year.
• ImmuPharma is focused on developing peptide-based therapeutics, with its lead program, Lupuzor™, aimed at treating Lupus and other autoimmune diseases.

ImmuPharma plc (LON:IMM - Get Free Report)'s share price shot up 9.5% on Tuesday . The stock traded as high as GBX 14.20 ($0.19) and last traded at GBX 12.10 ($0.16). 23,646,498 shares traded hands during mid-day trading, an increase of 176% from the average session volume of 8,583,096 shares. The stock had previously closed at GBX 11.05 ($0.15).

ImmuPharma Price Performance

The firm has a market cap of £60.47 million, a price-to-earnings ratio of -1,359.55 and a beta of 1.53. The company has a fifty day moving average price of GBX 4.66 and a two-hundred day moving average price of GBX 3.39.

ImmuPharma (LON:IMM - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported GBX (0.38) EPS for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. On average, research analysts expect that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.